India Caps Trade Margins on Anti-Cancer Medicines
What happened
The Government of India informed the Supreme Court that trade margins on specified non-scheduled anti-cancer medicines will be capped at 30%. An expert committee will identify the medicines covered by the cap, and the NPPA will examine its recommendations. The Supreme Court also questioned whether similar scrutiny should extend to other medicines and medical products.
From indiatimes.com
Why it matters
The decision addresses concerns over excessive trade margins in healthcare, aiming to ensure quality care is sustainable and accessible. This action occurs while the Supreme Court is overseeing judicial challenges related to trade policy and trade law. The move is part of a broader effort to regulate drug pricing in the Indian market.
The Supreme Court is overseeing judicial challenges related to trade policy and trade law.
From indiatimes.com
Who's involved
- supreme courtHighest court overseeing judicial challenges related to trade policy
- Sanjay KumarMember of the Supreme Court
- John W. KittredgeChief Justice of the Supreme Court
- Nongmeikapam Kotiswar SinghFormer justice on the Supreme Court bench
- RanaHeld a tenure position at the Supreme Court
Keep exploring
The entities involved
-
supreme court
highest court in a jurisdiction